


PHARMACEUTICAL 2022

Epizyme Inc. Rank 261 of 466









PHARMACEUTICAL 2022

Epizyme Inc. Rank 261 of 466



The relative strengths and weaknesses of Epizyme Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epizyme Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Epizyme Inc. is the variable Net Income, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 101%, being 23% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	206,043
Cost of Goods Sold	10,498
Intangible Assets	42,849
Liabilities, Current	45,196
Liabilities, Non-Current	0
Other Assets	38,563
Other Compr. Net Income	0
Other Expenses	22
Other Liabilities	0
Other Net Income	-13,108
Other Revenues	37,427
Property and Equipment	1,545
Research and Development	130,966
Selling, General and Administrative Expense	133,955

Output Variable	Value in 1000 USD
Assets	289,000
Liabilities	45,196
Expenses	275,441
Revenues	37,427
Stockholders Equity	243,804
Net Income	-251,122
Comprehensive Net Income	-251,122
Economic Capital Ratio	101%

